Medigene AG: Medigene successfully raises EUR 20.7 million in oversubscribed private placement

Planegg (pta018/05.05.2017/08:40 UTC+2) NOT FOR DISTRIBUTION, PUBLICATION OR FORWARDING IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced that it has successfully raised EUR 20.7 million in gross proceeds through a significantly oversubscribed private placement via an accelerated book building transaction. Medigene issued 1,964,599, representing the maximal possible number of new shares from authorized capital excluding pre-emptive rights. Shares were allocated to institutional investors at a price of EUR 10.55 per share.

Guggenheim Securities, LLC and Baader Bank AG acted as the bookrunners and Trout Capital LLC acted as co-placement agent for the transaction.

The capital increase represents approximately of 9.7% of the currently outstanding shares and will increase the total number of registered shares after the issuance to 22.118.329. The new shares will be admitted to trading on the Frankfurt Stock Exchange. The issuance of new shares was resolved by the Executive Management Board and the Supervisory Board of Medigene today based upon their previous resolutions May 4, 2017 to launch a capital increase.

Dr. Thomas Taapken, Chief Financial Officer of Medigene, comments: "We are pleased to announce the successful placement of new shares. In addition to existing institutional shareholders, we were able to attract new healthcare specialised investors. This successful transaction underlines Medigene's progress and promising prospects and we are grateful for this strong demonstration of confidence."

Note: This press release does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States, Germany or any other jurisdiction. The shares (the "Shares") of Medigene AG (the "Company") may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares in the Company in the United States.

This publication constitutes neither an offer to sell nor a solicitation to buy securities.

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 200033-3301
E-Mail:	public.relations@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate